Background: Ankylosing spondylitis/axial spondyloarthritis (AS/Axial SpA) is a chronic inflammatory condition that typically affects younger people and often has a detrimental impact on their ability to work. There is little awareness of the condition among family, friends and employers which makes it difficult for those with AS/Axial SpA to have fulfilled working lives. We aimed to conduct in-depth semi-structured interviews with participants to identify the experiences regarding the disclosure of AS/Axial SpA to employers, colleagues, family and healthcare professionals which also included factors perceived as barriers or facilitators associated with this issue. Methods: Within this qualitative study, using an interpretive phenomenological paradigm, semi-structured interviews were conducted with ten participants with AS/Axial SpA. The interviews were recorded, transcribed and analysed thematically using a Framework analysis. Ethical approval and informed consent were obtained. Results: Analysis led to the following five themes being identified: Coping until diagnosis identifies symptoms that participants struggled to deal with and their personal journeys until being diagnosed that was usually delayed. Opening up about diagnosis describes the different experiences and challenges for participants in disclosing to the different groups. Looking for support provides insights into the different groups of people that participants turn to for support when disclosing their diagnosis and for managing symptoms. Sensing the stigma focuses on the different forms of stigma and the resulting psychosocial impact in their overall lives. Making others aware describes the perceived lack of general awareness about the condition and suggestions from participants on how to address this issue. Conclusion: Participants discussed their diagnosis and symptoms to varying levels with employers, family members, friends and healthcare professionals. They decided on the level of disclosure after assessing the risks and potential benefits. They were able to find support from work colleagues and family but this was sometimes riddled with challenges. In addition, the specialist physiotherapy team were able to offer much needed physical and psychological support. Despite disclosing their diagnosis, participants remained fearful of stigmatisation especially at work, resulting in psychological distress, which was amplified by the lack of awareness about the condition. Employers, healthcare professionals and family members should not underestimate the challenges faced by individuals when deciding whether to disclose this hidden disability. Offering support and encouragement to empower individuals with AS/Axial SpA to successfully disclose their diagnosis should they choose to should be taken into account as a routine element of clinical care. Disclosure statement: J.M.: Other: Speaker fees from AbbVie, Pfizer and UCB. R.S., E.G-C. and J.A.G. have declared no conflicts of interest. Background: Hip osteoarthritis (OA is a common, painful and disabling condition that is set to rise in prevalence given the ageing and increasingly obese population. International guidelines recommend both pharmacological and non-pharmacological treatments (particularly exercise) for patients with hip OA. Combined treatment approaches are recognized as potentially offering synergistic benefits. Physiotherapists already hold an important role in managing patients with hip OA through prescribing exercise programmes. Having recently been granted independent prescribing rights, physiotherapists are now ideally placed to deliver combined pharmacological and nonpharmacological treatments. This study aimed to explore how physiotherapists currently address analgesic use among patients with hip OA, and to explore their beliefs about the acceptability of prescribing for this patient group. Methods: A mixed methods study was undertaken. A cross-sectional questionnaire was mailed to 3126 physiotherapists in the United Kingdom. Self-reported approaches to analgesic use among patients with hip OA were explored using a case vignette and associated clinical management questions. Semi-structured telephone interviews were undertaken with a purposive sample of questionnaire responders (n ¼ 21) and analysed thematically. Results: The questionnaire response rate was 52.7% (n ¼ 1646), with 1148 (69.7%) reporting having treated a patient with hip OA in the last 6 months, the applicable response for analyses. Only 0.8% of responders currently practiced as a non-medic prescriber, with 44.7% expressing an interest in becoming an independent prescriber. Nearly all (98.3%) physiotherapists reported that they would address analgesic use for the patient with hip OA, but most commonly by advising the patient to discuss this with their GP (82.7%). In total, 56.2% would discuss optimal use of current medication, and 32.7% and 37.2% would discuss use of over the counter medications and supplements, respectively. Interviews revealed that variations in how physiotherapists addressed analgesic use were guided by their own experience or instinct rather than local or national policy. Concern over patient safety, for example side effects from poly-pharmacy, and a belief that it is not their remit, made some physiotherapists reluctant to go beyond giving even general advice about the analgesic ladder. Although many physiotherapists recognized the potential benefit of becoming an independent prescriber for patients with hip OA, in terms of convenience and reducing GP attendance, the additional responsibility centring on patient safety was a common barrier to them wanting to do so. Conclusion: Physiotherapists commonly reported referring patients with hip OA to their GP when addressing analgesic use, with more specific advice on analgesic use being variable. Although physiotherapists recognize the potential benefits of becoming an independent prescriber, more than half of responders did not want to take on this additional responsibility. More guidance on addressing analgesic use in patients with OA may help to align care with best practice and reduce onward referral to GPs. We assessed the feasibility of introducing a joint pain advisor into primary care to improve people's access to effective management by delivering the NICE core recommendations and lifestyle coaching. Methods: Two joint pain advisors began running clinics for people with chronic knee/hip pain in a primary care surgery. At an initial assessment ($30 min) the advisor assessed their pain and function, physical activity level, waist circumference and body mass; taught effective self-management strategies, weight control, exercise and pain management; used behavioural change techniques and motivational interviewing; set SMART goals; provided action/coping plans, monitoring and feedback; help construct personalized care plan; identified the patient's physical activity preferences (swimming, walking) and identified local availability; referred the patient to relevant agencies (dietician) if necessary. Patients were invited to return for a review ($30 min) 6 weeks and 6 months later, when the advisor repeated the outcome measures, assessed feedback progress and success, reinforced health messages and offered ongoing support, reassurance and encouragement. Qualitative interviews assessed people's opinions of the effectiveness and value. Results: 513 people used the service, mostly women (72%), most with predominently knee pain (81%). Drop out rates were high but between the initial assessment and 6-month follow-up improvements were seen across all outcomes: knee/ hip OA outcome score improved [pain (16.1%), function (15.9%) and quality of life (16%); waist circumference decreased by 6.4 cm, weight by 4.9 kg and BMI by 2.1; physical activity increased by 1.9 days walking 20 min/week and patients were able to do on average 5.8 more 'sit-to-stands' in 30 sec. Patient satisfaction was very high. They valued advice tailored to their individual needs, appreciated easier access to care, the convenience and familiarity of the service being in their local GP surgery. This translated into self-reported improvementss such as 'it worked. . .I got a big improvement', 'from February to April I wasn't walking, now I can' and 'I was 10 stone and went down to 9 stone' Conclusion: Introducing a joint pain advisor into primary care was feasible and quickly accepted. They deliver a more effective, efficient model of recommended care. People applied the advice and as a consequence clinical outcomes improved and expressed satisfaction with the redesigned service. We are now delivering the service with health trainers and health care navigators. Background: Long-term autoimmune inflammatory musculoskeletal conditions have psychological, physical and socio-economic implications. Patients are more likely to experience psychological distress (PD), including depression and anxiety. Early studies in type 2 Diabetes and inflammatory bowel diseases have observed disease specific distress (DSD), which is distinct from anxiety and depression. It is direct distress related to the impact and burden of living with a chronic disease and hence DSD can be conceptually and empirically differentiated from symptoms of PD. Although this concept is novel in RA and related conditions, the aim of this study was to explore if there is evidence of illness specific distress in chronic rheumatological conditions. Methods: A thematic secondary qualitative data analysis was undertaken retrospectively from 79 audio-recorded 1:1 interview transcripts from five existing data sets. These included patients with a diagnosis of Rheumatoid arthritis (RA), Myositis and Antiphospholipid syndrome (APS). Each transcript was uploaded onto a qualitative computer software programme. Codes were generated that comprised of mood, fatigue, pain, disability and social impact. Results: The analytical framework generated 9 key themes of distress, including pain, fatigue and fear of loss function/disability; acceptance and burden of disease, worry of prognosis/outlook and impact on relationships; medication and consultation. The identified themes were independently validated by a focus group with patients with rheumatic disease and the study supervisors. Conclusion: There is evidence from our study that disease-specific distress is present in patients with RA and related conditions. As known from the studies in diabetes, DSD seems distinct from anxiety and depression, because it exhibits independent associations to clinical outcomes. Future research needs to work prospectively with people with rheumatological conditions to develop a patient generated outcome measure (PGOM). Faculty of Health Sciences, University of Southampton, Southampton, UNITED KINGDOM Background: Osteoarthritis (OA) affects an estimated 8.5 million people in the UK. Joint pain is highly prevalent and can cause substantial personal and economic impact. Supporting and maximizing patient self-management skills for dealing with joint pain is identified as a key component for effective and efficient healthcare. Patients increasingly access self-management information via online and digital resources. Over 5 million adults have basic literacy skills in the UK. To be widely accessible, it is recommended that healthcare information is written at a reading level of sixth grade or below (<11 years). Lower literacy levels have been associated with poor health outcomes and reduced ability to self-manage. Clear uncomplicated health messages informed by behavioural change theory, visual information and seeing similar people managing joint pain successfully have been identified as helpful to support people with OA to adopt self-management techniques. No previous research has reported the accessibility of websites for people with joint pain. This study aimed to evaluate the accessibility of health care websites by measuring readability, picture:text ratio and video inclusion. Methods: 8 key search terms agreed upon with patient and public involvement (joint pain, arthritis pain, hip pain, knee pain, hand pain; improving, treating, helping) were entered into the Google search engine. Webpages from the first page of Google search results were retrieved. Webpage text was assessed using the Simple Measure of Gobbledegook (SMOG) and the Gunning Fog Index. The picture:text ratio and number of videos included on each webpage was analysed. Results: 49 webpages from 16 websites met the inclusion criteria. Webpage reading grade levels ranged from 6.4 to 14.7 (SMOG) and 4.9 to 13.6 (FOG). SMOG analysis identified one webpage and FOG analysis identified 4 webpages as meeting recommended reading levels. Almost half (44.9%) of the webpages failed to include any relevant visual information to supplement text. Webpages from commercial websites had a higher picture:text ratio (mean 0.76 pictures per 100 words) than national government, professional and not-for-profit sites (mean 0.23 Background: In the UK, it is reported that 89% of adults follow the news and 31% read newspapers. Therefore newspapers have the potential to inform and influence a substantial proportion of the population. Recent scientific papers have been published on newspaper coverage of mental illness, oral cancer and gout. The language used by UK newspapers to report on rheumatoid arthritis (RA is an area we chose to systematically explore. Methods: The LexisNexis database was utilized to search for articles published in the 16 UK national non-specialist newspapers between 26 July 2011 and 26 July 2016, which contained the phrase 'rheumatoid arthritis' in the headline and/or lead paragraph. Articles were excluded if they were duplicates, product advertisements, letters seeking medical advice or only referred to RA once. The resultant articles were uploaded to NVivo Pro 11 software to aid thematic analysis. The first author systematically coded the dataset. A sample of the data were then cross-checked by the second author and agreement reached on final codes and themes. Results: The initial search query generated 413 articles of which 147 qualified for analysis: 106 (72%) appeared in tabloids and 41 (28%) in broadsheets. 81% of tabloid articles were printed in The Express, Daily Mail and Daily Mirror. The Daily Telegraph accounted for the majority (56%) of broadsheet articles. Across all newspapers, three themes were identified that used language to: 1) describe RA, 2) refer to those who live with RA, and 3) report potential new treatments. See Table 1 for popular coded words within these themes. Conclusion: Most newspaper articles about RA appear in tabloids where the language chosen to describe the condition tends to be negative and emotive, people who live with RA are often portrayed as helpless and potential new treatments are reported in an overly positive way (as much of the research highlighted is in its infancy). Overall, tabloid stories tend to be sensationalized with attentiongrabbing headlines, whereas RA articles in broadsheets are usually more factual with less use of emotive language. What impact the language used has on patients with RA is an interesting area for future research.
O20. HOW DO PHYSIOTHERAPISTS APPROACH ANALGESIC USE IN PATIENTS WITH HIP OSTEOARTHRITIS? FINDINGS FROM A MIXED METHODS STUDY
O24 Background: Patients with inflammatory arthritis often report flares of disease during times of psychological distress. This is particularly prevalent during adolescence, a time when mental health problems often become apparent. Increasing scientific evidence supports the concept that psychological stress and depression can promote inflammation. For patients with inflammatory arthritis, it is possible that this psychological distress-induced inflammation may cause worsened disease activity. This association has never been explored in detail for patients with juvenile idiopathic arthritis (JIA) or in a purely adolescent population. Methods: 135 patients with JIA between the ages of 13 and 18 years were recruited from University College Hospital, London and gave informed consent (mean age 16, 51.9% female). Each patient completed a questionnaire pack assessing anxiety (State-Trait Anxiety Inventory) and depression [Short Mood and Feelings Questionnaire (MFQ)]. On the same day, CRP, active joint count, disability (Childhood HAQ), pain [10cm visual analogue scale (VAS)] and physician's global assessment (PGA) (10cm VAS) were all recorded. 87 of these patients also donated a blood sample from which serum IL-6 and serum cortisol were measured by ELISA. Data were analysed using the Spearman's Rank Correlation Coefficient (r). Results: We found that 25% of adolescents with JIA scored over the MFQ cut-off for probable depression (>8 points). Depressive symptoms and anxiety associated with worsened disability (r ¼ 0.420, p < 0.001 and r ¼ 0.327, p < 0.001, respectively), pain (r ¼ 0.383, p < 0.001 and r ¼ 0.270, p < 0.01, respectively) and PGA (r ¼ 0.287, p < 0.01 and r ¼ 0.282, p < 0.01, respectively). Depressive symptoms also associated with active joint count (r ¼ 0.225, p < 0.01). CRP and IL-6 associated with active joint count (r ¼ 0.335, p < 0.001 and r ¼ 0.348, p < 0.001, respectively), disability (r ¼ 0.244, p < 0.05 and r ¼ 0.287, p < 0.01, respectively), pain (r ¼ 0.305, p < 0.01 and r ¼ 0.304, p < 0.01, respectively) and PGA (r ¼ 0.269, p < 0.01 and r ¼ 0.246, p < 0.05, respectively). Cortisol associated with lower pain (r¼À0.230, p < 0.05) and PGA scores (r¼À0.261, p < 0.05). There were no associations between CRP, IL-6, cortisol and psychological parameters. Conclusion: We found that a high proportion of JIA patients experienced significant depressive symptoms. This preliminary data analysis showed that disease activity measures associated with higher levels of inflammatory markers as well as worsened depressive symptoms and anxiety. However, depressive symptoms and anxiety did not associate with any serological inflammatory markers, which would be expected if mood was a driver of inflammation. The results hence imply that low mood primarily occurs as a consequence of pain and inflammation in adolescents with JIA. Longitudinal studies and further analyses of other inflammatory pathways would aid in better defining directionality. Disclosure statement: The authors have declared no conflicts of interest. Background: Juvenile-onset systemic lupus erythematosus (JSLE) is an autoimmune disorder characterized by immune cell dysregulation, chronic inflammation and increased cardiovascular risk. Disease onset dominates mid-puberty and the female:male ratio is 4.5:1, suggesting a hormonal importance in disease pathogenesis. JSLE patients have more aggressive disease, more major organ involvement and increased standardized mortality ratios compared to patients with adult-onset SLE. Our previous findings show that defects in immune cell lipid metabolism contribute to disease pathogenesis in adult-onset SLE. However, in JSLE little is known about the immune profile or whether abnormal lipid metabolism also contributes to pathogenesis. Here we performed in-depth immune and metabolic profiling in a cohort of JSLE patients and age and gender matched healthy controls (HCs). Methods: Flow cytometry was carried out using 2 15-colour panels to immunophenotype peripheral blood mononuclear cells from 32 HCs (10 male, 22 female, mean age 18) and 32 JSLE patients (8 male, 24 female, mean age 19). Data were analysed by cluster and phenotypephenotype correlation. Flow cytometry and qPCR were used to measure functional and metabolic marker expression on immune cell subsets. Data were correlated with clinical assessments of disease. Results: Patients with JSLE were characterized by increased naïve and decreased memory B-cell and T-cell subsets and increased monocyte frequency (p ¼ 0.0013) compared to HCs. CD4 þ and CD8 þ T-cells from JSLE patients had elevated membrane lipid raft (p ¼ 0.0185, p ¼ 0.0087) and glucose transport receptor (GLUT-1) (p ¼ 0.0205, p ¼ 0.0017) expression suggesting that they were more metabolically active. Furthermore the metabolic immuneophenotype in JSLE correlated positively with erythrocyte sedimentation rate and negatively with complement protein C3 supporting the hypothesis that altered metabolism is associated with JSLE disease features.
O26. STRATIFICATION OF PATIENTS WITH JUVENILE-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS USING IMMUNE AND METABOLIC PHENOTYPING
Comparison of HC males vs females revealed gender differences in the immune phenotype; in particular regulatory T cells from healthy males had an increased frequency and increased lipid raft (p ¼ 0.0387) and GLUT-1 (p ¼ 0.0306) expression compared to healthy females but in JSLE patients these gender differences were lost. Unsupervised hierarchical cluster analysis revealed that JSLE patient subgroups could be stratified based on their immuneophenotype and gender. Furthermore, phenotype-phenotype correlation analysis identified unique associations between immune cell subtypes comparing HC vs JSLE cohorts, male vs female HCs, healthy males vs JSLE males and healthy females vs JSLE females. This analysis revealed that different cell types could be involved in JSLE pathogenesis depending on gender. Conclusion: Gender differences in immunological and metabolic profiles and altered lipid metabolism could contribute to the bias of JSLE towards females. Disclosure statement: The authors have declared no conflicts of interest. Background: Non-infectious paediatric uveitis is an important cause of visual impairment in childhood. Non-infectious uveitis may be associated with a systemic inflammatory condition -most commonly JIA. Biologic therapies are proven to be more effective than DMARD therapy alone and hence have revolutioniZed the management of previously refractory patients. Little evidence of visual outcomes and complications associated with paediatric non-infectious uveitis in the era of biologic therapy exist. Therefore, this service evaluation was conducted to assess our population following the introduction of biologic therapies. Methods: This was a single centre retrospective chart based observational review. Patients diagnosed with non-infectious uveitis before the age of 16 and were managed at the Bristol Eye Hospital between 2007 and 2015 were included. Data were collected at baseline, 1, 3, 5 and 10 years. Data collected include demographics and referral information, relevant medial history, ophthalmological examination findings, ophthalmological complications and medical and surgical treatment provided. Results: Of the 166 patients included, 59% were female and 77.1% Caucasian. Average age at diagnosis was 8.06 years. 56% were tertiary referrals. At baseline, 30.1% (50) of patients had unilateral and 69.9% (116) of patients had bilateral disease. 22% of patients with unilateral uveitis progressed to bilateral uveitis. In total 293 eyes were included. 99 patients (59.6%) had a systemic inflammatory aetiology -92 (55.4%) had JIA. The majority of patients had anterior uveitis (75.3%). 89.8% received topical steroids and 77.1% required systemic treatment. 56 patients (33.7%) received biologic therapies. Adalimumab was the predominant biologic therapy (45 patients). 12 patients received multiple biologic agents. A total of 221 affected eyes were followed up at 1 year and 174 at 3 years. Visual impairment (worse than 6/12) at 1 year was 10.8% (24 eyes) and at 3 years 13.8% of affected eyes (25 eyes). Severe visual impairment (6/60 or worse) at 1 year was 0.9% (2 eyes) and at 3 years 6.3% (11 eyes) of affected eyes. Over a variable follow up of between 1 and 10 years, 21.5% of affected eyes developed posterior synechiae, 13% cataracts and 13% band keratopathy. Cataract surgery was the predominant surgical procedure (7.8% of affected eyes). 2 eyes were enucleated. Conclusion: One third of children received a biologic therapy, reflecting increasing utilization and importance of biologic agents in the management of inflammatory conditions. The majority of patients were tertiary referrals, this may have inflated the rate of complications and visual impairment. Despite this, the rate of visual impairment reported in this review is lower than reported in some studies prior to the introduction of biologic agents. This adds further to the evidence that biologic agents are an important treatment avenue in the management of paediatric non-infectious uveitis. Background: Lower limb synovitis is common in juvenile idiopathic arthritis (JIA). Cross-sectional studies suggest that along with synovitis, walking difficulties are also present; however there are no longitudinal studies reporting their prevalence rates from disease onset and change over time. Therefore, the aim of this study was to determine the prevalence of lower limb synovitis and walking disability and its course from first presentation of JIA (baseline) over 5 years. Methods: The Childhood Arthritis Prospective Study (CAPS) is a longitudinal study of children under 16 years of age who were recruited with a new JIA diagnosis. CAPS data collected include demographics and core outcome variables at baseline, 6 months and yearly thereafter. Synovitis was determined using active joint counts recorded at the hip, knee, ankle, subtalar, inter-tarsal (range 0-2), metatarsophalangeal (MTP) and interphalangeal (IP) joints (range 0-5), and dichotomized as present (1 or more) or absent (0). Walking disability was measured using the Childhood Health Assessment Questionnaire (CHAQ) walking subscale (range 0-3) and dichotomized as present (1 or more) or absent (0). The prevalence of lower limb synovitis and walking disability are expressed as percentages of participants. Change over time from baseline is expressed as percentages of participants with new or stable active synovitis and walking disability. Results: Data were available for 1,394 participants (median age 7.6 years, 64% female), dropping to 543 at 5 years. Baseline knee and ankle synovitis prevalence was 70% and 30% respectively, decreasing to approximately 15-20% and 10-15% after 1 year; of which 2.4% and 3.2% were new, and 12.9% and 5.7% were stable cases with active synovitis (Table 1) . Baseline hip and foot synovitis prevalence was less than 12%, decreasing to less than 5% after 1 year; of which 1% or less were new or stable active cases. At least mild walking disability was present in 52% at baseline, stabilizing at 25-30% after 1 year. Conclusion: Prevalence rates for knee and ankle joint synovitis and walking disability are initially high and then stabilize. Persistent walking disability affects a significant proportion of children with JIA after 1 year despite low prevalence rates of lower limb synovitis. the most common childhood inflammatory rheumatic diagnosis, affecting 1 in 1,000 UK children. In recent years great advances in dissecting the genetic basis of JIA have been made. In one landmark study, conducted on the two most common subtypes (oligoarthritis and RF-negative polyarthritis), 17 susceptibility loci were identified at genome-wide significance (p-value<5 Â 10 À8 ) with a further 11 reaching suggestive significance (p-value<1 Â 10 À6 ). The findings from this study were the results of a large international collaboration using the ImmunoChip array, a custom-made array targeting 186 known loci in 12 autoimmune diseases. However, one limitation to the aforementioned study was that the analysis was limited to the selected loci. Large genome-wide studies are now needed; therefore, the aim of this work is to identify novel genetic loci associated with disease susceptibility using a large cohort of UK JIA cases. Methods: Whole-genome genotyping data was generated using four platforms (Illumina). Following stringent quality control common variants to all four platforms were extracted from the individual datasets before merging together. Imputation was performed using the Haplotype Reference Consortium panel on the Michigan Imputation Server using Minimac3 software. SNPs with imputation accuracy (r 2 >0.5), minor allele frequency >1% and Hardy-Weinberg p-value >1 Â 10 À3 were retained for analysis. Association was conducted using logistic regression; using the top three principal components as covariates. Bioinformatics analysis was performed using in-house Capture Hi-C data, to study long-range interactions, to elucidate the potential function of the associated SNPs. Results: Post-QC, 2,585 JIA cases and 5181 controls were available for analysis with $7.4 million SNPs. Analysis conducted within oligoarthritis and RF-negative polyarthritis cases, (n ¼ 1,617) confirmed 13 previously identified JIA risk loci and identified more than 20 potentially novel regions above suggestive significance (2.25 Â 10
O27. OUTCOMES OF NON-INFECTIOUS PAEDIATRIC UVEITIS IN THE ERA OF BIOLOGIC THERAPY

O28. SUBCUTANEOUS ABATACEPT IN PATIENTS WITH POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC OR NON-BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS: PHARMACOKINETICS, EFFICACY AND SAFETY
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). Of these, rs7874896, an intergenic SNP located between TNFSF15 and TNFSF8 on chromosome 9 was one of the most strongly associated (pvalue 3.67 Â 10 À7 ). TNFSF15 is particularly interesting as by homology and function, is very similar to TNF-a. Furthermore, in Crohn's disease, it has been found that TNFSF15 drives expression of pro-inflammatory cytokines (IFN-g) and TNF-a from CD4 þ
CD161
þ T-cells, yet these cells were found to be resistant to anti-TNF treatment, suggesting that blockade of TNFSF15 may possess therapeutic benefit. Further investigation of SNPs within the TNFSF15/TNFSF8 gene region using Capture Hi-C data yielded potentially interesting interactions both within this region and with nearby genes within T-and B-cell lines. Conclusion: This study represents the largest GWAS conducted in JIA to date and our preliminary results have identified novel associations with the most common subtypes of the disease and may have highlighted a potentially novel therapeutic target. Background: Rheumatoid arthritis (RA) is a multifactorial disease associated with failure of immune tolerance. Advances in our understanding of the disease immunopathology have led to the development of biologic drugs targeting components of the immune response that drive disease progression (including TNF-a). However, these drugs are not effective in all individuals and many patients fail to respond. The ability to predict patient responses to conventional and to biologic treatment would improve the clinical management of patients with RA. Here we propose a novel immunophenotyping approach to identify unique signatures that could stratify patients for a more personalized approach to treatment of this complex disease. Methods: We optimized a novel high through-put immunophenotyping platform, LEGENDScreen, measuring the expression of 332 cell surface markers on B cell and T cell populations. We used this multi-dimensional approach to screen 31 RA patients, either treated with DMARDs or with adalimumab, as well as 18 healthy controls (HCs). The antigen-specific fluorescence intensity for each subset was examined. Differentially expressed markers (DEMs) between patient groups were determined using multiple unpaired t-test analysis (p < 0.05). The results guided us to further stratify the data looking at B cell subsets, disease activity (DAS28) and immunogenicity (presence or absence anti-drug antibodies (ADA), measured by ELISA), and accounting for treatment effect. Results: We identified phenotypic markers that were able to define RA patients, regardless of treatment, developing an 'immune signature' that differentiates these patients from HCs and from patients with SLE. We observed that the majority of DEMs, with significantly different expression between patient groups, were on CD19 þ B cells rather than CD4 þ T cells, confirming the contribution of B cells in the pathogenesis of RA. Identifying 26 DEMs that were significantly differentially expressed on B cells (p < 0.05). Further stratification of B cells, looking at immature, mature, and memory subsets, identified as many as 73 DEMs on memory B cells as well as 50 and 41 DEMs on immature and mature B cells respectively. Thus identifying additional markers that were not observed at a whole B cell level. In addition, we identified a unique immunohenotype associated with the lack of response to adalimumab and the development of ADA. Conclusion: This novel strategy of patient classification based on shared immune characteristics could lead to a better understanding of the disease and ultimately predict response to treatment. The predictive capacity of these immune signatures is being assessed in a prospective cohort of patients that have switched to adalimumab. Disclosure statement: The authors have declared no conflicts of interest. Background: Inflammatory bone loss is a common complication in chronic inflammatory arthritis. Glucocorticoids (GCs) are endogenous steroid hormones that are effective in treating chronic inflammatory disease, but exacerbate systemic bone loss. In vivo, tissue availability of GCs is dependent on the enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11b-HSD1), which converts inactive cortisone to active cortisol. Within bone 11b-HSD1 is potently increased by inflammation, where its role is poorly defined. Methods: To examine the contribution of glucocorticoids activated by 11b-HSD1 to inflammatory bone loss, we crossed a global 11b-HSD1 null mouse (that lacks the capacity to activate glucocorticoids) onto a TNF-a-driven model of chronic inflammatory arthritis (TNF-Tg) to generate a TNF-Tg/HSD1KO mouse. Histology of tibia and bones of the hind paw were assessed by micro-CT and in paraffin embedded sections. Serum markers of bone metabolism were assessed by ELISA and gene expression of osteoblast and osteoclasts within bone determined by real-time RT-PCR. Total osteoclast numbers within bone were determined by TRAP staining. Results: At 9 weeks TNF-Tg/HSD1KO mice had greater juxta articular and systemic bone loss compared to TNF-Tg animals on a wild type background, with increased cortical bone erosions, decreased trabecular bone volume (decreased 70%; p < 0.0005), decreased trabecular thickness (TNF-Tg 66 mm vs TNF-Tg/HSD1KO 45.3 mm; p < 0.005) and decreased trabecular number (decreased 68.2%; p < 0.005). Serum markers of bone formation and gene expression of osteoblast markers were significantly decreased in the TNF-Tg/ HSD1KO mouse (P1NP, Runx2 and osteoprotegerin reduced by 16%, 33% and 81% respectively; p < 0.05). In contrast, markers of bone resorption and osteoclast numbers at sites of bone loss, while elevated relative to wild type animals, remained constant between TNF-Tg/HSD1KO and TNF-Tg mice.
O32. LOCAL ACTIVATION OF ENDOGENOUS GLUCOCORTICOIDS ATTENUATE BONE LOSS IN CHRONIC INFLAMMATORY ARTHRITIS
Conclusion: These results demonstrate that in this murine model of chronic inflammatory arthritis, local glucocorticoids production by 11b-HSD1 protect against systemic inflammatory bone loss at sites of local joint destruction and systemically. While osteoclast bone resorption appeared similar between TNF-Tg/HSD1KO and TNF-Tg mice, bone formation by osteoblasts appeared to be attenuated in 11b-HSD1 null animals. Therefore 11b-HSD1 may mediate its protective effects by preserving bone formation in the presence of inflammation. Disclosure statement: The authors have declared no conflicts of interest. Background: The treatment of rheumatic diseases can be both expensive and ineffective with up to 1/3 of patients failing to respond to current treatments. There is therefore a need to identify new treatments and to target these to individuals. Although genetic studies have been successful in identifying common variation associated with disease susceptibility, a large proportion of these lie outside proteincoding regions. Many show enhancer activity but it is often unclear which gene(s) they regulate and how they contribute to disease. Chromatin folding brings linearly distant areas of the genome, such as promoters and enhancers, into close proximity, driving gene expression. Capture Hi-C (CHi-C) interrogates these interactions in a highthroughput, high-resolution manner, linking implicated enhancers to causal genes. Utilizing our existing CHi-C data on 3 rheumatic diseases, RA, JIA and PsA, targeting all known genetic associations, we explored the potential to identify candidate causal genes that are targets for existing drugs, which could be repositioned for use in these diseases. Methods: Chromatin interaction data for T-and B-cells in the 3 diseases was analyzed using CHiCAGO using a score cut-off of ! 5. Interactions between disease regions and promoters were identified using BEDTOOLS and intersected with drug targets from DrugBank. Existing treatments for each disease were identified by the presence of the relevant name in the indication field. Results: Overall 850 genes were identified as interacting with a disease associated region. Of these, 61 are existing drug targets (303 drugs) (Table 1 ) and 9 are existing therapies used in the treatment of disease, primarily RA. Conclusion: Our study identifies genes which are implicated in disease, are the target of existing drugs and offer the potential for drug repositioning. Of the potential drugs identified for RA, 14 are used in the treatment of various cancers and 11 are used in the treatment of diabetes and multiple sclerosis. Interestingly, 17 potential drugs identified for PsA are used in the treatment of schizophrenia and 11 in the treatment of hypertension. These data show a novel insight into how functional annotation of genetic associations in rheumatic diseases can provide gene targets for re-positioned therapies.
O33. (YOUNG INVESTIGATOR AWARD WINNER) CHROMATIN INTERACTIONS REVEAL NOVEL GENE TARGETS FOR DRUG REPOSITIONING IN RHEUMATIC DISEASES
O33 Disclosure statement: The authors have declared no conflicts of interest.
O34. ANTI-PHOSPHOLIPID ANTIBODIES DIFFERENTIALLY REGULATE THE EXPRESSION AND ACTIVITY OF THE LYSOSOMAL PROTEASES WITH EFFECTS UPON MONOCYTE AUTOPHAGY
Vera M. Ripoll, Akif Khawaja, Ian P. Giles and Anisur Rahman Centre for Rheumatology, Division of Medicine, University College London, London, UNITED KINGDOM Background: Antiphosholipid antibodies (aPLs) are known to activate monocytes in the pathogenesis of antiphospholipid syndrome (APS), although the precise mechanisms by which this activation occurs are not fully understood. We have recently identified several novel protein targets using a comprehensive proteomic analysis of human monocytes treated with IgG from patients with APS. Among these novel targets lysosomal proteases, including cathepsin B and cathepsin D were identified. These proteases are important in protein degradation, clearance of autolysosomes and autophagy. Dysregulation of these homeostatic cellular functions may be important in the exposure of autoantigens and pathogenesis of the APS. Therefore, we have now studied the effects of APS IgG upon the expression/activity of different cathepsins and their effects on autophagy. Methods: Healthy monocytes were treated with 200 mg/ml of IgG purified from nine patients with APS and nine healthy controls (HCs) IgG for 6 h. The expression of cathepsin B and cathepsin D was measured by western blotting. Activity assays for lysosomal proteases cathepsin D, cathepsin B and cathepsin L were performed using fluorescence based assays (RayBio). Intracellular proteolytic activity of monocytes was determined using DQ-BSA (Molecular Probes) and flow cytometry analysis. Results: Consistent with our previous label-free quantification mass spectrometry proteomic analysis, western blot analysis confirmed that levels of cathepsin B and cathepsin D were decreased in monocytes treated with APS IgG compared to HC IgG. Similarly, enzymatic assays revealed that cathepsin B and cathepsin D activities were significantly reduced in monocytes treated with IgG from patients with APS compared to HCs (p ¼ 0.0188, 0.0323). In contrast, levels of enzymatic activity of cathepsin L were increased in monocytes treated with APS IgG compared to HC IgG (p ¼ 0.0106). To determine the effect of APS IgG on autophagy, we exposed healthy monocytes to IgG and induced autophagy by treating them with GM-CSF for 14 h. Subsequently we tested the intracellular proteolytic activity with DQ-BSA. Stimulation of monocytes with APS IgG reduced the lysosomal activity of GM-CSF-treated monocytes significantly more than HC IgG indicating that APS IgG disrupts lysosomal degradation during monocyte autophagy. Conclusion: We found that IgG from patients with APS regulate the expression and activity of lysosomal proteases cathepsins B/D and cathepsin L in opposite directions. Activity of cathepsin B and D was down-regulated by exposure to IgG from patients with APS whereas cathepsin L was up-regulated. Furthermore, we found APS IgG disrupts lysosomal degradation during monocyte autophagy. Additional experiments are now under way to increase our understanding of how modulation of cathepsin activity and autophagy may be important in the pathogenesis of APS and provide new therapeutic targets. Disclosure statement: The authors have declared no conflicts of interest.
O35. THE AUTOIMMUNE GENETIC ARCHITECTURE OF CHILDHOOD-ONSET RHEUMATOID ARTHRITIS
Background: Genome-wide association studies have successfully identified susceptibility loci for many autoimmune diseases, including rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). About 5% of children with JIA have rheumatoid factor positive polyarthritis that is phenotypically similar to adults with seropositive RA, suggesting an extremely early onset of RA consistent with the childhood onset of RA (CORA). To better understand the genetic architecture of CORA risk relative to adult RA and other autoimmune diseases, we genotyped a cohort of CORA cases and controls on the Immunochip, a custom genotyping array. Methods: Immunochip genotyping was completed on 340 CORA cases and 11,624 controls. Following stringent SNP and sample QC, SNPs were tested for association with CORA using a logistic regression model with Caucasian admixture proportions (ADMIXTURE) as covariates (SNPLash). False discovery rate (FDR) adjusted p-values (P FDR ) are reported to account for the actual number of tests computed. Weighted genetic risk scores (wGRS) of top RA loci and JIA oligoarthritis and RF negative polyarthritis risk loci were calculated and logistic regression performed to assess whether the scores were good predictors of CORA. Receiver operator characteristic (ROC) curves were generated to define the sensitivity and specificity of each wGRS and the area under the curve (AUC) was calculated.
Results: The HLA region was strongly associated with CORA (rs3129769, p ¼ 3 Â 10 À25 ). Outside the HLA region, 33 regions had !1 SNP meeting P FDR <0.05. The two best signals of association were a region on 22q13 (rs9610687, OR ¼ 0.57, P FDR ¼0.0002) near RAC2 and the PTPN22 locus (rs6679677, OR ¼ 1.83, P FDR ¼0.0005). 17 of the 44 top RA hits and 6 of the 27 oligoarthritis and RF negative polyarthritis risk loci were associated with CORA. The wGRS for RA hits better predicted CORA (AUC¼0.71) than the wGRS for oligoarthritis and RF negative polyarthritis risk loci (AUC¼0.59), suggesting that CORA is more similar to RA than oligoarticular and RF negative polyarticular JIA. Conclusion: Analysis of the Immunochip in the largest cohort of CORA cases investigated to date has identified several loci associated with CORA, many of which are variants known to be associated with RA.
The FDR-based threshold also enabled us to identify several potential SNP associations not previously implicated in RA. Analysis of the two different wGRS for RA and oligoarticular and RF negative polyarticular JIA suggests that CORA shows more similarity with adult RA than with the most common subtypes of JIA. Acknowledgements: Juvenile Arthritis Consortium for Immunochip (JACI), computing provided by Wake Forest University Center for Public Health Genomics. Background: Better understanding of epigenetic regulatory mechanisms in Rheumatoid arthritis (RA) pathogenesis will facilitate the development of new biomarkers or therapeutic strategies. MicroRNAs are post-transcriptional regulators that coordinate cell activation by fine-tuning multiple intracellular pathways. We recently observed that microRNA-155 is upregulated in RA B cells, particularly in anticitrullinated protein antibodies (ACPA) positive RA patients. Therefore we sought to focus on the functional contribution of miR-155 in the B cells and its expression in the follicular structures of the RA synovium tissues. Methods: miR-155 expression in RA synovial tissues and synovial B cells was evaluated by in situ hybridization combined with CD20 staining (n ¼ 5). To asses the endogenous levels of miR-155 in B cells subsets; CD19 þ B cell of healthy controls and RA patients (2010 ACR/ EULAR classification criteria) (n ¼ 7 each) were stained with cell lineage-specific antibodies against naïve and memory subsets (CD27, CD38, IgD and IgM) and sorted with FACS AriaIII followed by qRT-PCR. To functionally evaluate the role of miR-155 in RA B cell activation: enriched CD19 þ B cells of ACPA-positive RA patients (n ¼ 6) were transfected with miR-155 inhibitors (miR-155I) or control inhibitor (CI). 48h later, quantitative RT-PCR was performed to identify transcription factors that regulate the B cell transcriptome and are under control of miR-155 (PAX5, PRDM1, PU.1 and IRF4). To evaluate antibody production (IgG and IgG-ACPA), CD19
þ cells of ACPApositive RA patients (n ¼ 5) were transfected with miR-155I or CI were stimulated with a plate-bound CD40 ligand (2 mg/ml), BAFF (100 ng/ml), IL-21 (50 ng/ml) and anti-IgM (5mg/ml) or left unstimulated for 7 days. Supernatants were assessed for the presence of total IgG and IgG-ACPA using standard or immune scan ELISA, respectively. Results: miR-155 is abundantly expressed in B cells of RA synovium; CD20 cells in ectopic follicular structures in RA synovium expressed high levels of miR-155. miR-155 expression in sorted B cell subsets: naïve, CD27 Background: Tocilizumab (TCZ), a humanized monoclonal antibody that blocks the interleukin-6 receptor, is approved for use as a first or subsequent biologic disease modifying agent in adult rheumatoid arthritis and in JRA. Its use is licensed with or without concurrent methotrexate and this along with its comparable tolerability and availability as a weekly self-administered subcutaneous injection has made this treatment an increasingly popular choice with patients and clinicians. As with other biologic agents the most frequent adverse events reported are infections. We describe a series of three patients with recurrent and persistent aphthous oral ulcers which developed while on TCZ. Methods: Patient 1: 75 y/o male treated with TCZ (iv for 12 months then converted to s/c) for seronegative RA without MTX. Reported persistent painful ulceration of the lateral border of the tongue 2 yrs after onset of TCZ. Biopsy confirmed high grade dysplasia. Patient 2: 40 y/o male treated with IV TCZ and MTX for severe seronegative inflammatory polyarthritis and nephrotic syndrome secondary to amyloidosis. Developed moderate oral ulceration 18 months after starting TCZ. Although the TCZ resulted in remission of arthritis and amyloidosis, this patient stopped TCZ due to painful oral ulcers. Patient 3: 84 y/o seropositive RA female patient treated with TCZ without MTX developed mouth ulcers 6 months after treatment onset. This progressed, leading to withdrawal of TCZ at 9 months. Results: Our series describes the occurrence of aphthous mouth ulcers induced by TCZ. The causative role of TCZ was established by positive re-challenge in patients 1 and 2. Once noted the problem progressed with confirmation of dysplastic features on biopsy in patients 1 and 2. A Health Watch website has recently reported a cohort of 82 cases of TCZ related mouth ulcers with 95% occurring within 6 months of treatment onset and 45% occurring in patients over 60 yrs old. Concurrent use of MTX or prednisolone does not appear to be relevant. In our cases retrospective inquiry confirms the symptoms started much earlier than reported. Conclusion: Although uncommon, this adverse reaction should be recognized early and withdrawal of TCZ seriously considered. Persistence with this specific biologic agent with or without ameliorating treatments like colchicine may be ill-advised as our experience suggests the ulcers are moderate to severely painful and in two of our patients showed dysplastic change over time on biopsy. Detailed inquiry at each routine monitoring assessment and dental surveillance is strongly recommended. Disclosure statement: The authors have declared no conflicts of interest.
O38. WHICH CAME FIRST, THE CHICKEN OR THE EGG?
Savvas Psarelis 1 and Elena Nikiphorou 2 1 Rheumatology, Nicosia General Hospital, Nicosia, CYPRUS and 2 Rheumatology, Whittington NHS Health, London, UNITED KINGDOM Background: Adult onset Still's disease (AOSD) is a chronic inflammatory disease with various manifestations including fevers, arthritis, and rashes. Although rare, meningoencephalitis has been described in patients with a severe form of this disease. Tocilizumab (IL6) inhibitor has been successfully used in severe and refractory cases of AOSD. Methods: A 21-year-old woman with known AOSD refractory to multiple treatments developed features of meningoencephalitis following the first dose of tocilizumab.
Results:
The patient first presented to general medicine with unremitting fevers and bilateral knee arthralgia, eventually diagnosed with AOSD. She required high dose steroids for acute symptomcontrol. Methotrexate and azathioprine (in sequence) were commenced as potential steroid-sparing agents, the former quickly discontinued due to side effects. Several months later she represented with fever, fatigue, loss of energy and arthralgia. Inflammatory markers were high and she was anaemic. The decision was taken to proceed with Tocilizumab. She tolerated this well, and her inflammatory markers and clinical symptoms rapidly improved. However, three weeks post the first infusion, the fevers recurred and she developed an erythematous rash with oedema over the lower legs, as well as debilitating headaches and confusion raising suspicion for meningoencephalitis. CT scan of the brain was unremarkable. A lumbar puncture revealed a CSF of: WBC 847 Â 10 9 /L (86% Neut, 9% Lym,), Glu 38mg/dl, Protein 404mg/dl. Ceftriaxone 2 g twice a day, Ampicillin 3g and Dexamethazone 4 mg twice a day were immediately commenced. Laboratory tests revealed CRP 257 mg/L, Hb 8.2 g/dL, WBC 6350 Â 10 9 /L. Gram stain and other microbiological tests were all negative. A second lumbar puncture four days later due to worsening symptoms showed: WBC 516 Â 10 9 /L (79% Neu, 14% lym) RBC 1165 Â 10 9 /L, Glu 52mg/dl, Protein 62mg/dl. The patient continued to worsen dropping her Glasgow Coma scale (9) and developing diplopia and verbal aphasia; MRI of the brain confirmed the suspected diagnosis of meningoencephalitis. High dose iv methylprednisolone was administered with rapid improvement in the patient's symptoms, leading to discharge home 11 days later, on prednisolone (starting at 1mg/kg) and leflunomide. It was subsequently revealed by the patient that she had discontinued all her medications following the first infusion of tocilizumab, as she felt better in herself. She is currently symptom-free on 2.5mg prednisone and leflunomide 20mg/day. Conclusion: This case demonstrates the dilemma of infection versus inflammation in the setting of autoinflammatory disease, as well as the importance of compliance to treatment. The onset of symptoms following the first tocilizumab infusion, raised concern regarding a potential infective complication of the drug. However, the negative microbiological tests, rapid response to steroids and the revelation from the patient that treatments were stopped, suggests that the meningoencephalitis was a consequence of the underlying autoinflammatory disease itself. Background: Anti-Zo (anti-phenylalanyl tRNA synthetase) antibodies were first described in idiopathic inflammatory myopathy (IIM) in 2007 and are associated with the anti-synthetase syndrome. They remain a relatively rare finding. We describe a patient with anti-Zo positive antisynthetase syndrome who has responded well to rituximab after failing standard second line agents. Methods: The patient was a 51yr old UK born Caucasian male mechanic and part-time football referee with no significant past medical history. Lifelong non-smoker. He was admitted in February 2013 with non-resolving pneumonia despite several courses of antibiotics. He was dyspnoeic on exercise and had a persistent cough and myalgia. Examination showed long cuticles with infarcts and apparent mechanics hands (these persisted even after he had stopped work). Investigations: CK 1303 iu/L (normal 40-320), ALT 84 iu/L (normal 0-50) and CRP 8.4 mg/L (normal 0-10). ANA, ANCA, Ig, C3 and C4 were negative/normal. Local ENA panel including Jo-1 and Scl-70 was negative. Royal Free screening including PL-7, PL-12, Ku, Mi2, PMScl and SRP was also negative. Initial lung function tests: FVC 3.44L (64% predicted), DLCO, 58% predicted. HRCT chest: extensive bilateral organizing pneumonia, particularly affecting the left base. Ba swallow: dysmotility and reflux.
Results: He was treated with prednisolone 40mg od and MMF 1g bd with slow normalization of CK over 3 months. Follow up HRCT showed persistent changes. At 5 months he was still steroid dependent (30mg) and was started on the Brompton cyclophosphamide regime for 6 months. As soon as this finished in February 2014 CK rose to 1003 iu/L despite prednisolone 15mg od. DLCO was 55%. At this point serum was sent to Bath for further antibody testing. This showed positive anti-Zo antibodies. IFR funding for rituximab was obtained (partly on the basis of this) and started in July 2014. By July 2015 he was steroid free and DLCO had improved to 64%. In July 2016 after a total of 4 courses of rituximab DLCO has further improved to 70%. CK remains normal and he has resumed football refereeing. He has remained steroid-free on single agent rituximab treatment. Conclusion: NHS England has now approved rituximab for use in patients with active myositis who have auto-antibodies relevant to myositis. This makes a detailed search for related antibodies crucial, even if initial basic screens are negative. It also supports the argument for further research to look for other synthetase syndrome-associated antibodies. The presence of reflux usually makes patients with interstitial lung disease ineligible for lung transplant; this lack of an end game means that aggressive and targeted early treatment is necessary and supports the now mandated use of a national database in this group of patients. Background: The use of FDG-PET/CT scanning is becoming more widespread in the investigation of pyrexia of unknown origin (PUO) with raised inflammatory markers to exclude rheumatological disorders. Methods: We report two cases of large vessel vasculitis fulfilling Petersdorf and Beeson criteria for PUO, where whole body FDG-PET/ CT scans were used successfully and unsuccessfully to diagnose vasculitis. Results: Case one is a 76 year old Caucasian male with stable seropositive ACPA positive rheumatoid arthritis on methotrexate monotherapy. Prednisolone 15mg was commenced in primary care for worsening arthritis. Weeks later he presented with recurrent fever, malaise, oral ulceration, fatigue and raised inflammatory markers (ESR 113mm/hr, CRP 283mg/l). Steroids were continued. Extensive microbiology, immunology, virology and imaging tests were unremarkable including CT of the thorax, abdomen and pelvis and MRI of the entire spine. An atypical right-sided headache developed without classic temporal tenderness, bruits or vascular signs. A 17mm inpatient temporal artery biopsy (TAB) was unremarkable. Subsequent negative tests included MRI, MRA, MRV of the brain; immunology; serial blood cultures; T-spot and lumbar puncture with cytology and virology. A FDG-PET/CT showed extensive large vessel vasculitis of the aorta, subclavian and right common carotid arteries. He was treated as giant cell arteritis (GCA), with IV methylprednisolone and oral corticosteroids. There was a rapid clinical improvement (CRP <4, ESR 5) at week 4. Case two is an 82 year old Caucasian male admitted with a one week history of fever, night sweats, malaise, hypoxia, with raised inflammatory markers (ESR of 132mm/hr, CRP 336). Following treatment for sepsis, he continued with fevers and abnormal tests. Opinions from infectious disease, microbiology, neurology, urology, and haematology were given. Investigations including unremarkable immunology; CT pulmonary angiogram; CT of the thorax, abdomen and pelvis; MRI of the entire spine; echocardiogram; lumbar puncture and extensive microbiology tests. He had no symptoms of headache, proximal limb girdle pain or features to suggest polymyalgia rheumatica. There were no bruits, temporal tenderness, or vascular signs. The FDG-PET/CT showed no evidence of vasculitis, occult sepsis, inflammation, or neoplasm. The malaise and fever settled with supportive therapy, inflammatory markers remained elevated. One month post discharge he presented with unilateral acute visual loss secondary to a central retinal artery occlusion, with acute headache. Treatment for GCA was commenced. Temporal artery biopsy (TAB) was confirmatory showing heavy trans-mural inflammation, internal elastic lamina disruption, and pathognomonic multinucleated giant cells. Conclusion: GCA can present as a PUO. These two cases highlight the utility and pitfalls of negative FDG-PET/CT and TAB when evaluating for large vessel vasculitis. Although steroids, and diabetes, can reduce the sensitivity of FDG-PET/CT, in case one where these factors were present, the scan was positive. In case two, without these factors, the scan was negative. Both FDG-PET/CT and TAB may be required in difficult cases. Disclosure statement: The authors have declared no conflicts of interest.
O41. PEMBROLIZUMAB THERAPY-INDUCED INFLAMMATORY ARTHROPATHY
Shianne Varrier and Patrick Kiely Rheumatology, St Georges Hospital, London, UNITED KINGDOM Background: We present a 69-year-old woman with no personal or family history of inflammatory arthritis who was diagnosed with epithelioid pleural mesothelioma. She failed to respond to cisplatin and Pemetrexed followed by 3 phase I trial agents. She was then treated with Pembrolizumab, an immune checkpoint inhibitor targeting the programmed death-1 (PD-1) pathway, which prevents natural inhibition of T cells and is effective against renal cell carcinoma, lymphoma and melanoma. She responded rapidly and the mesothelioma regressed. Within 48 hours of the first infusion she developed symmetrical pain and stiffness in the small joints of her hands, wrists and elbows, followed by knees, ankles and feet. Severity rapidly escalated and within days she was unable to walk or turn in bed due to pain. Treatment with NSAIDs and paracetamol were ineffective. Methods: On examination there was crepitus of the wrist extensors and hind foot tendons. There was also puffiness of the hands but minimal synovial swelling. Many joints were painful through passive movements. Ultrasound of the MCP, PIP and wrists showed synovial hypertrophy (GS) of 17/22 joints, grade 2 in 4 and grade 1 in 13, and power Doppler (PD) grade 1 in 5 joints. The wrist extensor tendons were both GS grade 1, and PD grade 1 on one side only. The knees were GS grade 1 with normal PD signal and the hind feet joints and tendons were all normal. Blood tests showed raised inflammatory markers (CRP 41, ESR 66), normocytic anaemia and weakly positive rheumatoid factor, but ACPA, ANA, ENA were negative. Results: She started treatment with a tapering schedule of prednisolone starting at 30mg. This was very effective and at 6 weeks she was mostly pain free with a return to normal physical function. Once steroids were weaned, and despite pembrolizumab being on hold, her arthritis rapidly flared again. Conclusion: Several case reports have described inflammatory disease following immune checkpoint inhibitor (ICI) therapy. By inhibiting natural suppression of T cell activation (CTLA4 or PD-1 pathways) a range of autoimmune sequelae are described including most commonly a maculopapular rash, colitis, pneumonitis, hepatitis and thyroiditis. Arthritis can present in either a typical RA pattern or an oligoarthropathy, and a sicca syndrome has been described. Our case was characteristic in demonstrating severe pain, as well as tendon crepitus, a particularly striking and unusual feature. As in our case, ultrasound findings tend to be modest but erosions have been described, and antibodies are either absent or weakly positive. Many cases demonstrate good response to high dose prednisolone, but often relapse once weaned, in which case anti-TNF therapies are reported to be beneficial. Disclosure statement: The authors have declared no conflicts of interest.
O42. SEVERE PYREXIAL ILLNESS FOLLOWING PNEUMOCOCCAL VACCINATION IN BEHÇ ET'S DISEASE
Lit Hiang Lee, Ian Gaywood and Philip Courtney Rheumatology, Queen's Medical Centre, Nottingham, UNITED KINGDOM Background: We report the case of a 44-year-old man with Behç et's disease who developed a severe pyrexial illness after pneumococcal and influenza vaccination. On the evening of vaccination, he developed pain in his right upper arm where he had the pneumococcal polysaccharide vaccine. The following day he became systemically unwell with fever, rigors, vomiting and diarrhoea. His condition deteriorated the subsequent day. On arrival at hospital, he was found to be hypotensive, tachycardic and pyrexial. He had a diffusely swollen, erythematous and tender right upper arm. Blood tests revealed stage 3 acute kidney injury, CRP of 500 and serum lactate of 7.
